Vivamedicus, UAB - financials and debts

Company age: 9 y. 11 mo.

Update

Vivamedicus - Company finances

EUR
2018
From: 2018-01-01
To: 2018-12-31
2019
From: 2019-01-01
To: 2019-12-31
2020
From: 2020-01-01
To: 2020-12-31
2021
From: 2021-01-01
To: 2021-12-31
2022
From: 2022-01-01
To: 2022-12-31
2023
From: 2023-01-01
To: 2023-12-31
2024
From: 2024-01-01
To: 2024-12-31
2025
From: 2025-01-01
To: 2025-12-31
Financial data
Sales revenue 92,459 208,536 218,212 407,418 514,710 407,732 410,014 272,346
Profit before tax 71,017 108,971 91,285 138,226 144,774 75,669 108,478 38,047
Net profit 67,430 103,493 86,709 117,409 124,118 64,112 92,003 31,860
Equity 70,180 106,243 110,599 169,184 178,597 140,980 115,336 93,672
Liabilities 4,709 16,126 8,567 92,670 45,916 64,599 19,900 32,313
Non-current assets 8,867 7,917 13,541 86,362 68,178 38,314 31,818 45,875
Current assets 65,857 114,304 105,369 175,144 156,039 166,238 102,506 79,130
Total assets 74,724 122,221 118,910 261,506 224,217 204,552 134,324 125,005
Taxes paid
STI taxes - - - - - 91,580 80,510 59,809
Social insurance contributions - - - - - 14,220 20,098 12,494
Financial indicators
Revenue change y/y +304.1% +125.5% +4.6% +86.7% +26.3% -20.8% +0.6% -33.6%
ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. 90.2% 84.7% 72.9% 44.9% 55.4% 31.3% 68.5% 25.5%
ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. 96.1% 97.4% 78.4% 69.4% 69.5% 45.5% 79.8% 34.0%
Profit margin Net profit margin. Shows the overall profitability of the company. 72.9% 49.6% 39.7% 28.8% 24.1% 15.7% 22.4% 11.7%
EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. 76.8% 52.3% 41.8% 33.9% 28.1% 18.6% 26.5% 14.0%
Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. 0.1 0.2 0.1 0.5 0.3 0.5 0.2 0.3
Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. 92,459 104,268 109,106 47,010 53,709 39,779 50,724 33,348

Purchase full financial statements

Profit/Loss, Balance Sheet, Cash Flow, Equity

9.99 € + PVM Buy

See Scoris data in Google Search

Mark Scoris as a favorite source. One click, no registration.

Vivamedicus - Social security debts

From To Debt, €
2026-08-26 2026-08-29 0.19
2026-08-23 2026-08-23 0.19
2026-08-19 2026-08-19 0.19
2026-07-23 2026-08-12 0.19
2024-04-23 2024-05-08 0.41
2023-07-26 2023-08-10 0.92
2023-07-24 2023-07-25 0.99
2023-05-04 2023-05-07 2.82
2023-04-25 2023-04-25 2.82
2023-03-16 2023-03-20 19.74
2023-01-17 2023-01-23 1177.08
2021-11-16 2021-12-05 0.02
2021-10-18 2021-10-20 0.02

Vivamedicus - VMI tax arrears

From To Overdue, €
2025-09-28 2025-09-29 3319.37
2025-08-28 2025-08-28 2846.71
2025-07-28 2025-07-28 2200.49
2025-05-17 2025-05-17 4869.01
2025-05-09 2025-05-16 4637.87
2025-02-23 2025-02-26 22.04
2025-02-20 2025-02-22 22.0
2025-02-13 2025-02-13 3074.94
2024-11-28 2024-12-08 1.18

VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.

Analysis of the company's financial position

This description was generated by artificial intelligence. Report if inaccurate.
Vivamedicus, UAB (code 304411429) is a Private Limited Liability Company engaged in medical specialists activities. In the latest financial year, 2025, the company generated revenue of €272.3K and net profit of €31.9K, corresponding to a profit margin of 11.7%. Revenue declined by 33.6% year on year and was also 33.2% below the 2023 level, showing a clear contraction after a stronger 2024. The profit trend followed the same direction: net profit increased from €64.1K in 2023 to €92.0K in 2024, then eased to €31.9K in 2025. Total assets at year-end 2025 amounted to €125.0K, supported by equity of €93.7K and liabilities of €32.3K. The equity ratio remained high at 74.9%, while debt to equity stood at 0.34. Asset turnover was 2.18x, indicating efficient use of the asset base. Revenue per employee was €34.0K and profit per employee was €4.0K.